Simon T Barry

Simon T Barry

UNVERIFIED PROFILE

Are you Simon T Barry?   Register this Author

Register author
Simon T Barry

Simon T Barry

Publications by authors named "Simon T Barry"

Are you Simon T Barry?   Register this Author

60Publications

2160Reads

47Profile Views

Preclinical Evaluation of AZ12601011 and AZ12799734, Inhibitors of Transforming Growth Factor Superfamily Type 1 Receptors.

Mol Pharmacol 2019 02 20;95(2):222-234. Epub 2018 Nov 20.

Cancer Research UK Beatson Institute, Garscube Estate, Bearsden, Glasgow, United Kingdom (L.C.S., G.J.F., B.H., O.J.S., G.J.I.);Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom (O.J.S., G.J.I.) Division of Cellular Medicine, School of Medicine, University of Dundee, Dundee, United Kingdom (R.G.T., L.S.S.); and AstraZeneca Bioscience, Oncology (G.D.H., S.T.B., B.R.D.) and Medicinal Chemistry, Oncology (F.W.G.), IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/mol.118.112946DOI Listing
February 2019

Evaluation of dynamic contrast-enhanced MRI biomarkers for stratified cancer medicine: How do permeability and perfusion vary between human tumours?

Magn Reson Imaging 2018 02 14;46:98-105. Epub 2017 Nov 14.

Centre for Imaging Sciences, Division of Informatics Imaging & Data Sciences, School of Health Sciences, Faculty of Biology Medicine & Health, University of Manchester, Manchester Academic Health Sciences Centre, Manchester M13 9PL, UK; Formerly AstraZeneca, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK; Bioxydyn Ltd., Rutherford House, Manchester M15 6SZ, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.mri.2017.11.008DOI Listing
February 2018

Developing PreDICT - a fully integrated data platform for preclinical in vivo data: learning from experience.

Drug Discov Today 2017 10 9;22(10):1539-1546. Epub 2017 Aug 9.

IMED Oncology, AstraZeneca Oncology, Cambridge, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.drudis.2017.07.014DOI Listing
October 2017

Automated image analysis of intra-tumoral and peripheral endocrine organ vascular bed regression using 'Fibrelength' as a novel structural biomarker.

J Appl Toxicol 2017 08 10;37(8):902-912. Epub 2017 Feb 10.

AstraZeneca PLC, Oncology iMED, Alderley Edge, Cheshire, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jat.3438DOI Listing
August 2017

Tumour regression and improved gastrointestinal tolerability from controlled release of SN-38 from novel polyoxazoline-modified dendrimers.

J Control Release 2017 02 30;247:73-85. Epub 2016 Dec 30.

AstraZeneca, Pharmaceutical Sciences, Innovative Medicines, Silk Court Business Park, Macclesfield, Cheshire SK10 2NA, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jconrel.2016.12.034DOI Listing
February 2017

Challenges and strategies in anti-cancer nanomedicine development: An industry perspective.

Adv Drug Deliv Rev 2017 01 29;108:25-38. Epub 2016 Apr 29.

Innovative Medicines-Oncology, AstraZeneca, CRUK Cambridge Institute, Cambridge, CB2 0RE, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.addr.2016.04.025DOI Listing
January 2017

Modelling the tumour microenvironment in long-term microencapsulated 3D co-cultures recapitulates phenotypic features of disease progression.

Biomaterials 2016 Feb 19;78:50-61. Epub 2015 Nov 19.

iBET, Instituto de Biologia Experimental e Tecnológica, Oeiras, Portugal; Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Oeiras, Portugal. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.biomaterials.2015.11.030DOI Listing
February 2016

Modulation of FAK and Src adhesion signaling occurs independently of adhesion complex composition.

J Cell Biol 2016 Feb;212(3):349-64

Wellcome Trust Centre for Cell-Matrix Research, Faculty of Life Sciences, University of Manchester, Manchester M13 9PT, England, UK

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1083/jcb.201508080DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4739608PMC
February 2016

PDGFR Inhibition Results in Pericyte Depletion and Hemorrhage into the Corpus Luteum of the Rat Ovary.

Toxicol Pathol 2016 Jan 3;44(1):98-111. Epub 2015 Nov 3.

AstraZeneca, Oncology iMed, Alderley Park, Macclesfield, Cheshire, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0192623315613452DOI Listing
January 2016

Tumour stromal morphology impacts nanomedicine cytotoxicity in patient-derived xenografts.

Nanomedicine 2015 Jul 6;11(5):1247-52. Epub 2015 Mar 6.

Oncology iMed, AstraZeneca, Macclesfield, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.nano.2015.02.007DOI Listing
July 2015

Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.

Cancer Cell 2015 Jan 24;27(1):109-22. Epub 2014 Dec 24.

Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Weill Cornell Medical College, New York, NY 10065, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2014.11.008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4293347PMC
January 2015

Mechanisms that influence tumour response to VEGF-pathway inhibitors.

Biochem Soc Trans 2014 Dec;42(6):1601-7

*Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K.

View Article

Download full-text PDF

Source
http://biochemsoctrans.org/lookup/doi/10.1042/BST20140261
Publisher Site
http://dx.doi.org/10.1042/BST20140261DOI Listing
December 2014

Tumor stromal phenotypes define VEGF sensitivity--response.

Clin Cancer Res 2014 Oct;20(19):5141

Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-0681DOI Listing
October 2014

Therapeutic targeting of integrin αvβ6 in breast cancer.

J Natl Cancer Inst 2014 Aug 28;106(8). Epub 2014 Jun 28.

Affiliations of authors: Centre for Tumour Biology (KMM, GJT, KB, AS, SV, RB, IRH, JLJ, JFM), Cancer Screening Evaluation Group (SWD, JW, RG, PC), and Molecular Oncology and Imaging (SH, CC), John Vane Science Centre, Barts Cancer Institute, Queen Mary University of London, London, UK; Department of Histopathology, Molecular Medical Sciences, Nottingham City Hospital NHS Trust, Nottingham, UK (IOE, ARG); Cancer Sciences Division, Southampton General Hospital, Southampton, UK (GJT, DE, WJT); Department of Surgery (AMT, PQ) and Department of Pathology (LJ), Ninewells Hospital and Medical School, Dundee, UK; Hedley Atkins Breast Pathology Laboratory, Guy's Hospital, London, UK (CG); Cancer Research UK Centre for Epidemiology, Mathematics and Statistics, Wolfson Institute of Preventative Medicine, Queen Mary University of London, London, UK (AB); Biogen Idec, Cambridge, MA (SV, PHW); Oncology iMED, AstraZeneca, Macclesfield, UK (JK, STB).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/dju169DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4151855PMC
August 2014

Tumor stromal architecture can define the intrinsic tumor response to VEGF-targeted therapy.

Clin Cancer Res 2013 Dec 12;19(24):6943-56. Epub 2013 Sep 12.

Authors' Affiliations: Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire; and Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-1637DOI Listing
December 2013

High-content analysis to leverage a robust phenotypic profiling approach to vascular modulation.

J Biomol Screen 2013 Dec 9;18(10):1246-59. Epub 2013 Oct 9.

1Discovery Sciences, AstraZeneca R&D, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1087057113499775DOI Listing
December 2013

Model-based drug discovery: implementation and impact.

Drug Discov Today 2013 Aug 29;18(15-16):764-75. Epub 2013 May 29.

Global Drug Metabolism and Pharmacokinetics, Innovative Medicines, AstraZeneca, Södertälje, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.drudis.2013.05.012DOI Listing
August 2013

Inhibition of neutrophil infiltration into A549 lung tumors in vitro and in vivo using a CXCR2-specific antagonist is associated with reduced tumor growth.

Int J Cancer 2011 Aug 13;129(4):847-58. Epub 2011 Apr 13.

Academic Unit of Inflammation & Tumor Targeting, Faculty of Medicine, Health and Dentistry, University of Sheffield, Sheffield, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.25987DOI Listing
August 2011

Placental growth factor neutralising antibodies give limited anti-angiogenic effects in an in vitro organotypic angiogenesis model.

Angiogenesis 2010 Dec 16;13(4):337-47. Epub 2010 Oct 16.

Cancer Bioscience, AstraZeneca, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10456-010-9190-0
Publisher Site
http://dx.doi.org/10.1007/s10456-010-9190-0DOI Listing
December 2010

The integrin alphavbeta3 is a receptor for the latency-associated peptides of transforming growth factors beta1 and beta3.

Biochem J 2003 Jan;369(Pt 2):311-8

Department of Systems Research, GlaxoSmithKline Research and Development, Gunnels Wood Road, Stevenage SG1 2NY, U.K.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1042/BJ20020809DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1223078PMC
January 2003

Paxillin associates with poly(A)-binding protein 1 at the dense endoplasmic reticulum and the leading edge of migrating cells.

J Biol Chem 2002 Feb 9;277(8):6428-37. Epub 2001 Nov 9.

Department of Biochemistry, University of Leicester, University Road, Leicester, LE1 7RH, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M109446200DOI Listing
February 2002